Dr. Rod Ray, CEO and Chairman at Bend Research, discusses his company’s approach to difficult drug delivery challenges and the core technologies offered by his company.
Dr. Jean-Luc Herbeaux, the Head of the Health Care Business Line of Evonik, discusses the rationale and success of his company’s latest acquisition.
Contributor Cindy H. Dubin interviewed leading players in the prefilled syringe market to find out about their offerings and how they are addressing pharma’s needs for safety, ease of use, cost, and product differentiation.
Robert Gwozdz, MPharm, presents an overview of polymers used in the more exotic and technically challenging dosage forms involving MR as well as those used for enhancing the dissolution and bioavailability of poorly soluble APIs.
Mr. Ben Moga, President of Ratio, Inc., talks about his company’s focus on self-injection in a homecare setting and how Ratio is pitting the patch injector against conventional autoinjectors in what is projected to be a $15.8 billion injectable drug delivery device market.
James D. Ingebrand, VP & General manager of 3M DDS, discusses his priorities for the years ahead and recent developments in 3M’s technologies.
DRUG DEVELOPMENT – Design & Development of Atorvastatin Orally Disintegrating Tablets & Their Evaluation by Electronic Tongue
Rakesh Kumar Bhasin, MPharm, and Pradip Kumar Ghosh, PhD, design and develop a good taste-masked atorvastatin ODT that matched the in vitro release profile of Lipitor.
FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
Unilife CEO, Alan Shortall discusses his company’s unique business model , transformational approach to the market, and his thoughts on how to move forward.
EXCLUSIVE ONLINE CONTENT
Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
Hovione Acquires ExtremoChem & Its Portfolio of Proprietary Sugars to Support Customers With Stabilization & Delivery of Biopharmaceuticals
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
In Cayman Currents Issue 36, Cayman Chemical showcases the ongoing discoveries and innovation advancing lipid nanoparticles (LNPs) to the forefront of modern medicine and highlights tools available to support LNP research.
Acumen Pharmaceuticals & Halozyme Enter Global Collaboration & License Agreement to Develop Subcutaneous Formulation of ACU193 With ENHANZE Technology
Acumen Pharmaceuticals, Inc. recently announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc. to provide Acumen access to Halozyme’s ENHANZE drug delivery technology, based on….
Cambrex recently completed the sale of its Drug Product Business Unit to Wilmington, DE- based Noramco. Cambrex’s Drug Product business provides….
MARKET NEWS & TRENDS
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
WEBINAR – Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation
In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….
The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing. Since these devices….
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
WHITEPAPER – Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance
To gain insights into advanced copolymer characterization techniques and their impact on drug release in biomedical products, we invite you to explore the latest Corbion white paper…..
WHITEPAPER – The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation
This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations…..
WHITEPAPER – Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination
This paper covers the benefits of the LBF and capsules combination in dosage form developments, an efficient technology platform to bring efficient and differentiated products to the market.
In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and….
Going forward, sponsors developing ophthalmic products formulated for delivery as eye drops must be prepared to pursue development programs that address the regulatory requirements for drug-device combination products. Partnering with a contract manufacturing organization (CMO) that has experience bringing such products to market is essential…..